Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI7247
- Development stage
- Phase 1
- Lead developer
- MedImmune
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MEDI7247 is a first-in-class antibody-drug conjugate (ADC) designed for the treatment of hematological malignancies and selected solid tumors. It consists of a human monoclonal antibody targeting the sodium-dependent alanine-serine-cysteine transporter 2 (ASCT2, also known as SLC1A5), which is overexpressed in various cancers. The antibody is site-specifically conjugated via a protease-cleavable linker to a highly cytotoxic pyrrolobenzodiazepine (PBD) dimer payload, which acts as a DNA cross-linking agent. This design enables targeted delivery of the cytotoxic agent to ASCT2-expressing tumor cells while sparing normal tissues with low ASCT2 expression. MEDI7247 has been evaluated in phase 1 clinical trials for relapsed or refractory acute myeloid leukemia (AML), multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), and advanced/metastatic solid tumors[1][5][6].
- Other names
- anti-ASCT2 antibody-drug conjugate MEDI7247anti-ASCT-2 antibody-drug conjugate MEDI7247anti-ASCT 2 antibody-drug conjugate MEDI7247
02
Targets
SLC1A5 (Alanine/serine/cysteine transporter 2)
Beyond the preview
Go deeper on MEDI7247.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI7247.